Xenon Pharmaceuticals (XENE) Competitors

Xenon Pharmaceuticals (NASDAQ:XENE) and Ascendis Pharma A/S (NASDAQ:ASND) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Does the MarketBeat Community favor XENE or ASND?

Ascendis Pharma A/S received 24 more outperform votes than Xenon Pharmaceuticals when rated by MarketBeat users. However, 70.15% of users gave Xenon Pharmaceuticals an outperform vote while only 66.82% of users gave Ascendis Pharma A/S an outperform vote.

Company	Underperform	Outperform
Xenon Pharmaceuticals	Outperform Votes 423 70.15%	Underperform Votes 180 29.85%
Ascendis Pharma A/S	Outperform Votes 447 66.82%	Underperform Votes 222 33.18%

Do analysts rate XENE or ASND?

Xenon Pharmaceuticals currently has a consensus target price of $57.38, indicating a potential upside of 63.55%. Ascendis Pharma A/S has a consensus target price of $204.64, indicating a potential upside of 26.21%. Given Xenon Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Xenon Pharmaceuticals is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.93

Which has more risk & volatility, XENE or ASND?

Xenon Pharmaceuticals has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500.

Which has better valuation & earnings, XENE or ASND?

Xenon Pharmaceuticals has higher earnings, but lower revenue than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$9.43M	284.74	-$182.39M	-$3.02	-11.62
Ascendis Pharma A/S	$363.64M	27.06	-$409.12M	-$7.10	-22.84

Is XENE or ASND more profitable?

Xenon Pharmaceuticals has a net margin of 0.00% compared to Ascendis Pharma A/S's net margin of -104.54%. Ascendis Pharma A/S's return on equity of 0.00% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-24.69%	-23.68%
Ascendis Pharma A/S	-104.54%	N/A	-39.23%

Does the media favor XENE or ASND?

In the previous week, Xenon Pharmaceuticals and Xenon Pharmaceuticals both had 7 articles in the media. Xenon Pharmaceuticals' average media sentiment score of 1.05 beat Ascendis Pharma A/S's score of 0.84 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders believe in XENE or ASND?

95.4% of Xenon Pharmaceuticals shares are held by institutional investors. 5.5% of Xenon Pharmaceuticals shares are held by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Xenon Pharmaceuticals beats Ascendis Pharma A/S on 12 of the 17 factors compared between the two stocks.